medigraphic.com

2012, Number 2

<< Back Next >>

Rev Cuba Endoc 2012; 23 (2)

Characterization of the metabolic control in children and adolescents with type I diabetes mellitus

González FP, Álvarez GMA, Cabrera RE, Bejerano RCJ, Albertine LM

Language: Spanish
References: 35
Page: 117-127
PDF size: 99.16 Kb.


ABSTRACT

Introduction: the metabolic control is the main objective of the diabetes mellitus treatment.
Objective: to characterize the metabolic control in a group of children and adolescents with type I diabetes mellitus.
Methods: a prospective study was conducted in 84 patients with type 1 diabetes mellitus, who had been seen at the endocrinology service of "William Soler" university pediatric hospital from February 2010 to August 2011. Glycated haemoglobin (HbA1c) was estimated in a period of 90 to 120 days. The quantitative turbidimetric method served to determine hemoglobin A1c by using Futura System reagent. The quarterly results of HbA1c were compared by age, sex, time of evolution of diabetes mellitus, body weight in kg and total daily dosage of insulin.
Results: the average age of male patients was 11.6 years (SD= 4,6) and of female patients was 12.4 years (SD= 4.5). The mean age at the beginning of the study was 12.23 years (SD= 4.42) and the mean age at time of diagnosis was 8.27 years (SD= 4.28). The average time of evolution for diabetes was 3.79 years (SD= 3.17) and the daily mean dose of insulin per kg of bodyweight was 0.91 units (SD= 0.26). The HbA1c values were kept over 10 %, except for the two last estimations that showed significantly lower values than those of previous months and were not dependent on the variables sex, time of evolution, age at time of diagnosis and daily average dose of insulin per kilogram of bodyweight.
Conclusions: adequate clinical relation and improved adherence to treatment are decisive elements for the improvement of the metabolic control in these patients.


REFERENCES

  1. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.

  2. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Derived Average Glucose (ADAG) Study Group. Translating the A1c Assay into Estimated Average Glucose Value. Diabetes Care. 2008;31:1473-8.

  3. Behan KJ, Merschen J. HbA1c does not always estimate average glucose. Clin Lab Sci. 2011;24:71-7.

  4. Srisurin W. Prevalence and Effect of Hemoglobin E Disorders on HbA1c and Lipid Profile of Diabetic Patients at Surin Hospital. J Med Assoc Thai. 2011;94:36-42.

  5. Jain N, Kesimer M, Hoyer JD, Calikoglu AS. Hemoglobin raleigh results in factitiously low hemoglobin A1c when evaluated via immunoassay analyzer. J Diabetes Complications. 2011;25:14-8.

  6. National Glycohemoglobin Standardization Program [homepage en internet]. Factors that interfere with GHB Test Results. [citado 10 de junio de 2011]. Disponible en: http://www.ngsp.org/factors.asp

  7. Thomas LB, Agosti SJ, Man MA, Mastorides SM. Screening for Hemoglobinopathies During Routine Hemoglobin A1c Testing Using the Tosoh G7 Glycohemoglobin Analyzer. Ann Clin Lab Sci. 2007;37:251-5.

  8. Thomas A. Standardization of HbA1c measurement-the issues. Diabetic Medicine. 2000;17:2-4.

  9. Behan KJ, Storey NM, Lee HK. Reporting variant hemoglobins discovered during hemoglobin A1c analysis-common practices in clinical laboratories. Clin Chim Acta. 2009;406(1-2):124-8.

  10. Jaisson S, Guillard E, Leroy N, Gillery P. Comparaison des interferences analytiques sur le dosage de l'HbA1c par deux analyseurs de chromatographie liquide haute pression. Ann Biol Clin. 2011;69:63-9.

  11. Grosse SD, Boulet SL, Amendah DD, Oyeku SO. Administrative data sets and health services research on hemoglobinopathies: a review of the literature. Am J Prev Med. 2010;38(4 Suppl):S557-67.

  12. Bleyer AJ, Vidya S, Sujata L, Russell GB, Akinnifesi D, Hire D, et al. The impact of sickle cell trait on glycated haemoglobin in diabetes mellitus. Diabet Med. 2010;27:1012-6.

  13. González Fernández P. Crecimiento y desarrollo en la drepanocitosis. Rev Cubana Endocrinol [serie en internet]. 2006 Abr [citado 25 de octubre de 2011];17(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532006000100006&lng=es&nrm=iso&tlng=es

  14. Sickle Cell Trait and other Hemoglobinopathies and Diabetes: Important Information for Physicians [homepage en internet] [citado 4 de octubre de 2011]. Disponible en: http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/SickleCell-Fact.pdf

  15. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27:1761-3.

  16. Laxmisan A, Vaughan-Sarrazin M, Cram P. Repeated hemoglobin A1C ordering in the VA Health System. Am J Med. 2011;124:342-9.

  17. Smellie WSA, Forth J, Bareford D, Twomey P, Galloway MJ, Logan ECM, et al. Best practice in primary care pathology: review 3. J Clin Pathol. 2006;59:781-9.

  18. Jordán RJ. Crecimiento humano en Cuba. La Habana: Editorial Científico Técnica; 1975. p. 35-114.

  19. Weinzimer SA, JAH Ahern, EA Doyle, MR Vincent, J Dziura, AT Steffen, et al. Persistence of benefits of continuous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics. 2004;114:1601-5.

  20. Minkina-Pedras M, Jarosz-Chobot P, Polanska J, Kalina MA, Marcinkowski A, Malecka-Tendera E. Prospective assessment of continuous subcutaneous insulin infusion therapy in young children with type 1 diabetes. Diabetes Res Clin Pract. 2009;85:153-8.

  21. Diabetes Research in children Network (DirecNet) Study Group. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care. 2009;32:1954-9.

  22. Chobot AP, Deja G, Marcinkowski A, Myrda A, Minkina-Pedras M, Jarosz-Chobot P, et al. Treatment of type 1 diabetes mellitus revealed below 7 years old age in the Diabetes Center of Silesia, Poland. Pediatr Endocrinol Diabetes Metab. 2007;13:75-8.

  23. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, et al. Hvidøre Study Group on Childhood Diabetes. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3 805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care. 2001;24:1342-7.

  24. González Fernández P, González Fernández C, Álvarez González MÁ, García Sáez J. Características clínicas de los episodios de hipoglucemia en niños y adolescentes con diabetes tipo 1 atendidos en el Hospital Pediátrico "William Soler". Rev Cubana Endocrinol. 2010 Dic;21(3):279-96.

  25. Sasigarn A, Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008;9(Part 1):197-201.

  26. Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr. 1999;134:486-91.

  27. Baena G, Carral F, Roca MM, Cayón M, Ortego J, Escobar L, et al ¿Es posible alcanzar en la práctica clínica los objetivos de control metabólico establecidos para pacientes con diabetes mellitus tipo1? Endocrinol Nutr. 2008;55:442-7.

  28. García-García E, Sánchez-Pérez R, Galera R, Aguilera P, Ramos J, Bonillo A. Monitorización continua de glucosa en niños tratados con bomba de insulina. Endocrinol Nutr. 2008;55:249-52.

  29. González Sarmiento E, Delgado Morales JL, Hinojosa Mena-Bernal MC, Fernández Galante I, Zurro Hernández J. Importancia de la monitorización continua de glucosa en el control de la diabetes mellitus tipo 1. Endocrinol Nutr. 2006;53:587-91.

  30. Gracia D. Bioética Clínica. Colección Ética y Vida. Estudios de Bioética. Tomo 2. 2da edición. Bogotá: Editorial Códice; 2001. p. 61-6.

  31. Laín Entralgo P. El médico y el enfermo. 2da edición. Madrid: Editorial Triacastela; 2003. p. 193-208.

  32. Nansel TR, Anderson BJ, Laffel LMB, Simons-Morton BG, Weisberg-Benchell J, Wysocki T, et al. A multisite trial of a clinic-integreated intervention for promoving family management of pediatric type 1 diabetes: feasibility and designs. Pediatric Diabetes. 2009;10:105-15.

  33. Nansel TR, Weisberg-BenchellJ, Wysocki T, Laffel LMB, Anderson BJ. Quality of live in children with type 1diabetes: a comparison of general and diabetes-specific measures and support for a unitary diabetes quality-of-life construct. Diabet Med. 2008;25:1316-23.

  34. Rossetti P, Porcellati F, Bolli GB, Fanelli CG. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(Suppl 2);31:S113-S120.

  35. Heller SR. Minimizing hypoglycemia while maintaining glycemic control in diabetes. Diabetes. 2008;57:3177-82.




2020     |     www.medigraphic.com